Intelligent Bio Solutions Initiates Clinical Study for FDA Submission of Drug Screening System
INBS has more than doubled off its 52-week low of $4.03.
Summary
Intelligent Bio Solutions announced the start of clinical studies to support a new FDA 510(k) submission for its fingerprint-based drug screening system, targeting U.S. market clearance for codeine detection.
Key Events · Product Development and Regulatory · INBS
-
Clinical Study Program Initiated
The company has commenced a clinical study program to support a new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System.
-
Targeting Codeine Detection
The studies are specifically designed for the detection of the opiate codeine, aiming to expand the system's utility beyond 'Forensic Use Only' in the U.S. market.
-
Partnership with Cliantha Research
Intelligent Bio Solutions is partnering with Cliantha Research, a clinical research organization, for the execution of these studies.
-
Anticipated Data Analysis
Full data analysis from the clinical studies is anticipated by the end of March 2026, with results to be incorporated into the FDA submission package.
Analysis · INBS · Industrial Applications And Services
This filing marks a significant operational milestone for Intelligent Bio Solutions, as it commences clinical studies crucial for its FDA 510(k) submission. For a medical technology company, securing FDA clearance is paramount for market access, especially in the multi-billion dollar U.S. drug screening market. The focus on codeine detection expands the system's capabilities beyond 'Forensic Use Only' and positions the company for broader commercial opportunities. This positive development follows recent financing activities, suggesting the company is now actively deploying capital towards product commercialization and regulatory approval.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.6% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $9.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.1M. The 52-week trading range was $4.03 to $27.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.